Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.48 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.45 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9928303 | 0.92 | TTBK1 (0.45) | EGFRERBB2TTBK1TTBK2DRD4 | |
| SCHEMBL9898236 | 0.85 | TTBK1 (0.44) | EGFRTTBK1TTBK2DRD4DRD3 | |
| SCHEMBL13471641 | 0.83 | BTK (0.53) | LIMK2ALDH1A1BTK | |
| SCHEMBL9928315 | 0.82 | EGFR (0.53) | EGFRERBB2KDRLCK | |
| SCHEMBL9943134 | 0.82 | EGFR (0.46) | EGFRERBB2KDRLCK | |
| SCHEMBL9904088 | 0.82 | EGFR (0.46) | EGFRERBB2KDRLCK | |
| SCHEMBL9904005 | 0.80 | EGFR (0.65) | EGFRERBB2KDRLCK | |
| SCHEMBL9903987 | 0.80 | ERBB2 (0.46) | EGFRERBB2KDRLCK | |
| SCHEMBL9943059 | 0.79 | EGFR (0.49) | EGFRERBB2BRAFTNNI3K | |
| SCHEMBL9903999 | 0.79 | EGFR (0.64) | EGFRERBB2TTBK1TTBK2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2511276-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | Ube Industries, Ltd. (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | ERBB2, EGFR, FGFR1 | EGFR 2/4885ERBB2 1/4885TTBK1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.